The ability of immune cells—particularly CD8+ T cells—to launch a rapid burst of proliferation inside tumors is key to the ...
An mRNA cancer vaccine carries its own immune booster and lights up when it starts working, showing treatment success in mice ...
Objective Macrophage activation syndrome (MAS), a subtype of secondary haemophagocytic lymphohistiocytosis (HLH), is a rare ...
First-in-human study results show all four hallmarks of T cell engager pharmacodynamics, validating CDR-Life's proprietary M-gager platform CDR-Life, Inc., a biotechnology company developing highly ...
Confirmation of 30mg efti as optimal biological dose relevant for Immutep’s oncology pipeline and potential future Biological ...
Meet the Jekyll and Hyde of the immune system: activated CD8⁺ T cells. On June 24 in Nature Immunology, researchers led by Dorian McGavern at the National Institutes of Health introduce a granzyme ...
In a breakthrough that could potentially rewrite the prevention and treatment of cancer, scientists have discovered how ...
Global Phase III trial has enrolled and randomised over 170 patients, reaching an important milestone as this is above the amount needed to ...
A recent article in Nature Communications describes a nanovaccine platform designed to support the development of personalized cancer vaccines. This approach uses tumor cell membranes enriched with ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback